在既往肝硬化患者中识别脓毒症的独特特征
该研究分析了单中心前瞻性队列中2962例重症脓毒症患者,其中371例(13%)有既往肝硬化诊断。肝硬化患者病情更重、更常见腹部感染源,且临床凝血异常更明显。多因素分析显示,肝硬化与急性肾损伤风险升高(校正OR 1.65;95%CI 1.21-2.26;P=0.002)和30天死亡率升高(校正OR 1.38;95%CI 1.05-1.82;P=0.022)相关,但急性呼吸窘迫综合征风险无显著差异(校正OR 1.02;95%CI 0.69-1.50;P=0.92)。血浆蛋白分析显示肝硬化患者血管生成素-2、血管性血友病因子和可溶性血栓调节蛋白水平更高,而白细胞介素-10、白细胞介素-1β和白细胞介素-1受体拮抗剂水平更低。
要点
- 在重症脓毒症患者中,既往肝硬化与急性肾损伤风险升高独立相关(校正OR 1.65;95%CI 1.21-2.26;P=0.002)。
- 既往肝硬化与30天死亡率升高独立相关(校正OR 1.38;95%CI 1.05-1.82;P=0.022)。
- 肝硬化与急性呼吸窘迫综合征风险无显著差异(校正OR 1.02;95%CI 0.69-1.50;P=0.92)。
- 肝硬化患者更常见腹部感染源,病情严重度评分更高,临床凝血异常更明显。
- 肝硬化患者血浆血管生成素-2、血管性血友病因子、可溶性血栓调节蛋白水平更高,白细胞介素-10、白细胞介素-1β、白细胞介素-1受体拮抗剂水平更低。
适用人群与场景
- 单中心前瞻性队列中的重症脓毒症成人患者,纳入2962例,其中371例(13%)有既往肝硬化诊断。
- 随访6天观察急性呼吸窘迫综合征和急性肾损伤发生,随访30天观察死亡率。
研究设计与关键结果
- 研究类型为单中心前瞻性队列,纳入2962例重症脓毒症患者,371例(13%)有既往肝硬化诊断。
- 肝硬化患者病情严重度评分更高,更常见腹部感染源,临床凝血异常更明显。
- 多因素分析:肝硬化与急性肾损伤风险升高相关(校正OR 1.65;95%CI 1.21-2.26;P=0.002),与30天死亡率升高相关(校正OR 1.38;95%CI 1.05-1.82;P=0.022),与急性呼吸窘迫综合征风险无显著差异(校正OR 1.02;95%CI 0.69-1.50;P=0.92)。
- 血浆蛋白:肝硬化患者血管生成素-2(P<0.001)、血管性血友病因子(P<0.001)、可溶性血栓调节蛋白(P<0.001)水平更高,白细胞介素-10(P<0.001)、白细胞介素-1β(P=0.008)、白细胞介素-1受体拮抗剂(P=0.036)水平更低;白细胞介素-6水平无显著差异(P=0.30)。
证据类型、等级与局限
- 证据类型:单中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,既往肝硬化合并脓毒症的患者可能表现为独特的内皮功能障碍表型,需要针对性的治疗策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The pre-existing diagnosis of cirrhosis is a complicating factor in the progression and prognosis of sepsis; however, the unique epidemiology, sepsis characteristics, and underlying mechanisms of immune dysregulation in sepsis among patients with cirrhosis remain incompletely understood. Our primary objective was to identify clinical outcomes and biological characteristics that differ between patients with and without cirrhosis among critically ill patients with sepsis.
METHODS: We analyzed data from a prospective cohort of critically ill patients presenting to single center with sepsis. Subjects were followed for 6 days for the development of acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI), and 30 days for mortality. Inflammatory, endothelial, and coagulopathic proteins were measured in plasma collected at ICU admission in a subset of patients. We determined associations of cirrhosis with outcomes using multivariable logistic regression adjusting for pre-specified confounders. We tested differences in plasma protein levels by cirrhosis diagnosis using the Wilcoxon Rank-sum test.
RESULTS: We enrolled 2962 subjects, 371 (13%) of whom had a pre-existing diagnosis of cirrhosis. Patients with cirrhosis had higher severity of illness scores, were more likely to have an abdominal source of sepsis, and had more significant clinically measured coagulation abnormalities relative to patients without cirrhosis. In multivariate analysis, cirrhosis was associated with higher AKI risk (adjusted OR 1.65; 95% CI 1.21 to 2.26; P = 0.002), and 30-day mortality (adjusted OR 1.38; 95% CI 1.05 to 1.82; P = 0.022). There was no significant difference in risk for ARDS (adjusted OR 1.02; 95% CI 0.69 to 1.50; P = 0.92). Cirrhosis was associated with higher plasma levels of angiopoietin-2 (P < 0.001), von Willebrand factor (P < 0.001), and soluble thrombomodulin (P < 0.001), as well as lower levels of interleukin (IL)-10 (P < 0.001), IL-1β (P = 0.008), and IL-1RA (P = 0.036). There were no significant differences in levels of IL-6 (P = 0.30).
CONCLUSIONS: We identified associations between pre-existing cirrhosis and endothelial injury, AKI, and mortality in sepsis. Patients with pre-existing cirrhosis who develop sepsis may display a unique phenotype of endothelial dysfunction that requires unique targeted approaches.
参考来源
- Dasgupta A, Jones TK, Giannini H, et al. Identifying a unique signature of sepsis in patients with pre-existing cirrhosis. Crit Care. 2025. PMID: 40390062. doi:10.1186/s13054-025-05423-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。